France mRNA Synthesis & Manufacturing Market (2024-2029)
The France mRNA Synthesis & Manufacturing Market was valued at $54.02 Million in 2024 and projected to reach to $68.52 Million by 2029, representing a compound annual growth rate of 4.9%. France's mRNA synthesis and manufacturing market is poised for sustained growth through 2029, driven by robust government backing and strategic investments in biopharmaceutical infrastructure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
France mRNA Synthesis & Manufacturing Market Trends and Insights
- France is establishing itself as a key player in Europe's mRNA ecosystem, driven by investments in biopharmaceutical infrastructure and government support for advanced manufacturing capabilities.
- The French market benefits from strong regulatory frameworks, established pharmaceutical expertise, and growing demand for personalized medicine and vaccine development. The expansion of France's mRNA sector through 2029 reflects increasing adoption of mRNA-based therapeutics and the country's commitment to reducing dependence on external manufacturing.
- France's position within the European Union enables access to broader markets and collaborative research initiatives.
- Key drivers include rising R&D spending, partnerships between academic institutions and industry players, and the development of contract manufacturing organizations (CMOs) specializing in mRNA production..
Key Market Statistics
- CAGR (2024-2029) 4.9% CAGR
- Market Size, 2024 ~USD 54.02 Million
- Forecast, 2029 ~USD 68.52 Million
- Country France
France mRNA Synthesis & Manufacturing Market Overview
Market Valuation Growth :
France's mRNA synthesis and manufacturing market reached $54.02 million in 2024, with projections to expand to $68.52 million by 2029, demonstrating steady market expansion at 4.9% CAGR.
Government Support & Infrastructure :
France is leveraging strategic government initiatives and substantial investments in biopharmaceutical infrastructure to position itself as a leading European hub for mRNA manufacturing and research capabilities.
European Ecosystem Leadership :
France is establishing itself as a key player within Europe's mRNA ecosystem, attracting biotech companies and fostering collaboration between academic institutions and pharmaceutical manufacturers.
Advanced Manufacturing Capabilities :
The country is developing cutting-edge manufacturing facilities and technological expertise to support mRNA-based therapeutics production, enhancing its competitive position in the global market.
France mRNA Synthesis & Manufacturing Market Dynamics
- The country's commitment to establishing advanced manufacturing capabilities positions it as a critical node in Europe's mRNA supply chain, attracting both domestic and international biotech investments. The 4.9% CAGR reflects France's measured but consistent expansion within the broader European context, where regulatory frameworks and innovation ecosystems continue to mature.
- Ongoing development of specialized facilities and skilled workforce capabilities will enable France to capture increasing market share in mRNA therapeutics manufacturing, supporting both domestic pharmaceutical companies and international partnerships..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Analytical And Scientific Instrumentation
- Environmental Testing
- Gas Chromatography
- Polymerase Chain Reaction (PCR)
- Automated Liquid Handling Systems
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Agilent Technologies, Inc.
- Shimadzu Corporation
- Merck KGaA
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Thermo Fisher Scientific Inc.
- SANOFI
- Merck KGaA
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- France's mRNA synthesis market is valued at $54.02 million in 2024 and will reach $68.52 million by 2029 at a 4.9% CAGR.
- France is leveraging government support and EU regulatory frameworks to strengthen its mRNA manufacturing capabilities and reduce external dependencies.
- Rising demand for personalized medicine and vaccine development is driving investment in France's mRNA infrastructure and CMO expansion.
- France's strategic position in Europe enables collaborative research and access to broader markets for mRNA-based therapeutics.
mRNA Synthesis & Manufacturing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | MRNA SYNTHESIS & MODIFICATION SERVICES (Service) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 5.8% from 2024 to 2029 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 2.23 (2024) |
| Revenue Forecast (Billions) | ~USD 2.96 (2029) |
| Segments Covered | Product, Type, Application, End User, Service, Consumables, Transcription Consumables, Purification Consumables, Analysis & Characterization Consumables |
France mRNA Synthesis & Manufacturing Market Report Segmentation
9 segment dimensions are covered across the global market.
By Product
- Consumables
- Instruments
By Type
- Analysis & Characterization Consumables
- Analysis Kits And Reagents
- Chromatography Filters & Membrane
- Mrna Profiling Kits
- Mrna Synthesis Kits
- Nucleotides
- Other Products
- Other Purification Consumables
- Other Transcription Consumables
- Plasmid Dna/Dna Templates
- Purification Consumables
- Purification Kits & Reagents
- Rna Polymerases
- Transcription Consumables
- Vectors
By Application
- Cell & Gene Therapies
- Other Applications
- Vaccines
By End User
- Academic & Research Institutions
- Cros & Cdmos
- Cros And Cdmos
- Pharmaceutical & Biotechnology Companies
- Small-Scale Cros & Cdmos
By Service
- Manufacturing & Scale-Up Services
- Mrna Analysis & Characterization Services
- Mrna Purification Services
- Mrna Synthesis & Modification Services
By Consumables
- Analysis & Characterization Consumables
- Purification Consumables
- Transcription Consumables
By Transcription Consumables
- Mrna Profiling Kits
- Mrna Synthesis Kits
- Nucleotides
- Other Transcription Consumables
- Plasmid Dna/Dna Templates
- Rna Polymerases
- Vectors
By Purification Consumables
- Chromatography Filters & Membranes
- Other Purification Consumables
- Purification Kits & Reagents
- Purification Kits And Reagents
By Analysis & Characterization Consumables
- Analysis Kits & Reagents
- Analysis Kits And Reagents
- Other Analysis & Characterization Consumables
FRANCE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTIONS | 19.4 | 14.3 | 14.3 | 14.9 | 15.6 | 16.3 | 17.1 | 18.2 | 4.9 |
| CROS & CDMOS | 16.3 | 12 | 12 | 12.4 | 13 | 13.7 | 14.3 | 15.2 | 4.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 45.8 | 33.6 | 33.9 | 35.2 | 37 | 38.9 | 40.8 | 43.5 | 5.1 |
| TOTAL | 81.6 | 59.9 | 60.3 | 62.5 | 65.6 | 68.9 | 72.3 | 76.9 | 5 |
FRANCE: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTIONS | 10.6 | 9.2 | 9.3 | 9.7 | 10.3 | 11 | 11.9 | 13.1 | 7.1 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 30.2 | 26.3 | 26.6 | 27.9 | 29.8 | 32.1 | 34.7 | 38.3 | 7.6 |
| SMALL-SCALE CROS & CDMOS | 3.6 | 3.1 | 3.1 | 3.2 | 3.4 | 3.6 | 3.9 | 4.2 | 6.3 |
| TOTAL | 44.4 | 38.6 | 39 | 40.8 | 43.5 | 46.7 | 50.5 | 55.6 | 7.4 |
Target Audience
- Biopharmaceutical Companies : Manufacturers and developers seeking to establish or expand mRNA production capabilities in France need detailed market data to evaluate facility investments, partnership opportunities, and competitive positioning within the French market.
- Investment & Venture Capital Firms : Investors targeting France's biotech sector require comprehensive market analysis to identify high-growth opportunities, assess portfolio company potential, and make informed funding decisions in mRNA manufacturing ventures.
- Government & Policy Makers : French regulatory bodies and economic development agencies use market intelligence to shape biopharmaceutical policies, allocate resources, and strengthen France's position as a European mRNA manufacturing leader.
- Contract Manufacturing Organizations (CMOs) : CMOs operating in or considering entry into France need market-specific data to evaluate demand, pricing strategies, capacity planning, and competitive dynamics in the French mRNA synthesis and manufacturing sector.
- Research & Academic Institutions : Universities and research centers in France require market insights to align research initiatives with commercial opportunities, secure funding, and collaborate effectively with industry partners in mRNA technology development.
Reasons to Buy this Report
- France-Specific Market Sizing : Access precise valuation data for France's mRNA market with verified 2024 baseline ($54.02M) and 2029 forecasts ($68.52M), enabling accurate financial planning and investment decisions tailored to the French market.
- Competitive Landscape Intelligence : Understand France's unique position within Europe's mRNA ecosystem, including local manufacturing capabilities, government support mechanisms, and competitive advantages versus other European markets.
- Investment & Partnership Opportunities : Identify strategic opportunities for partnerships, facility development, and market entry in France's growing biopharmaceutical sector with detailed insights into infrastructure investments and regulatory pathways.
- Growth Trajectory Analysis : Leverage France-specific CAGR data (4.9%) to benchmark performance, forecast revenue potential, and develop market penetration strategies aligned with the country's projected expansion through 2029.
- Regulatory & Policy Insights : Gain actionable intelligence on French government initiatives, manufacturing standards, and policy frameworks driving mRNA market development, essential for compliance and strategic planning in this jurisdiction.
Frequently asked questions
What is the current size of France's mRNA synthesis and manufacturing market?
France's mRNA synthesis and manufacturing market was valued at $54.02 million in 2024.
What is the projected market size for France's mRNA sector by 2029?
France's mRNA synthesis and manufacturing market is projected to reach $68.52 million by 2029.
What is the growth rate of France's mRNA synthesis market?
France's mRNA synthesis and manufacturing market is expected to grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2029.
What factors are driving growth in France's mRNA manufacturing sector?
Key drivers include government support for biopharmaceutical infrastructure, rising R&D spending, partnerships between academic and industry players, and increasing demand for personalized medicine and vaccine development in France.
How does France's mRNA market compare to other European countries?
France is establishing itself as a key player in Europe's mRNA ecosystem through strategic investments, strong regulatory frameworks, and collaborative initiatives that position it competitively within the broader European market.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the mRNA synthesis and manufacturing market. Exhaustive secondary research was done to collect information on the mRNA synthesis and manufacturing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as market share analysis, MnM repository analysis, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the mRNA synthesis and manufacturing market.
Secondary Research
The market for the companies offering mRNA synthesis and manufacturing solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product & service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. In the secondary research process, various secondary sources were referred to for identifying and collecting information related to the study. Secondary sources included annual reports, press releases, and investor presentations of blockchain vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and product-oriented perspectives.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global mRNA synthesis and manufacturing market scenario. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the pharmaceutical & biopharmaceutical industry) and the supply side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, as well as channels) across five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, and online, personal, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Top-down approache was used to estimate and validate the total size of the mRNA synthesis and manufacturing market. These methods include market share analysis, MnM repository analysis were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research.
- The revenues generated from the mRNA synthesis and manufacturing market business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Market Definition
mRNA synthesis and manufacturing refers to the process of producing messenger RNA (mRNA) through in vitro transcription, followed by various purification, and characterization steps to create high-quality mRNA products suitable for research, therapeutic, or vaccine applications. The mRNA synthesis and manufacturing market encompasses the development, production, and commercialization of messenger RNA (mRNA) products, including their synthesis via in vitro transcription, large-scale manufacturing, and formulation. This market serves various applications such as vaccines, therapeutic treatments, and potentially other areas like protein replacement. It involves specialized technologies and equipment, adherence to regulatory standards, and a global supply chain network.
The study provides an in-depth analysis of the mRNA synthesis and manufacturing market based on contemporary market trends and developments, and its potential growth from 2024 to 2029. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key mRNA synthesis and manufacturing product and service providers.
Stakeholders
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Development and Manufacturing Organizations (CDMOs)
- Raw Material Suppliers
- Market Research and Consulting Firms
- Regulatory Agencies
- Venture Capitalists
- Government Organizations
- Industry Associations and Professional Societies
Report Objectives
- To define, describe, and forecast the mRNA synthesis and manufacturing market based on product, service, application, and region
- To define, describe, and forecast the mRNA synthesis and manufacturing market based on product by end user and service by end user
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the mRNA synthesis and manufacturing market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global mRNA synthesis and manufacturing market and comprehensively analyze their products and services portfolios, market positions, and core competencies.
- To track and analyze competitive developments such as product/service launches, expansions, agreements, and collaborations in the mRNA synthesis and manufacturing market
- To benchmark players within the mRNA synthesis and manufacturing market using the Company Evaluation Matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Get the Full mRNA Synthesis & Manufacturing Market Report
Full forecast, segment splits, and company analysis for all mRNA Synthesis & Manufacturing Market.
- Canada mRNA Synthesis & Manufacturing Market
- US mRNA Synthesis & Manufacturing Market
- Germany mRNA Synthesis & Manufacturing Market
- UK mRNA Synthesis & Manufacturing Market
- Switzerland mRNA Synthesis & Manufacturing Market
- Italy mRNA Synthesis & Manufacturing Market
- Spain mRNA Synthesis & Manufacturing Market
- China mRNA Synthesis & Manufacturing Market
- Japan mRNA Synthesis & Manufacturing Market
- India mRNA Synthesis & Manufacturing Market
- South Korea mRNA Synthesis & Manufacturing Market
- Brazil mRNA Synthesis & Manufacturing Market
- Rest Of Europe mRNA Synthesis & Manufacturing Market
- Rest Of Asia Pacific mRNA Synthesis & Manufacturing Market
- Rest Of Latin America mRNA Synthesis & Manufacturing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
